Stay updated on MAPP2 MDMA Therapy Clinical Trial
Sign up to get notified when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.

Latest updates to the MAPP2 MDMA Therapy Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe study record version was updated from v3.5.3 to v3.5.4, representing a minor maintenance update to the ClinicalTrials.gov page. This change does not alter the study design, endpoints, eligibility criteria, or reported information.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe sponsor line now shows Resilient Pharmaceuticals as sponsor and responsible party, replacing Lykos Therapeutics. This change reflects a shift in the organization overseeing the study.SummaryDifference0.2%

- Check39 days agoChange DetectedThe page’s footer revision marker was updated from v3.5.2 to v3.5.3, indicating a general platform/version change without affecting the listed clinical trial study information.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check75 days agoChange DetectedTemplate revision updated to v3.5.0, replacing v3.4.3. No user-facing content or study data are affected.SummaryDifference0.0%

- Check82 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to MAPP2 MDMA Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.